| 4.84 0 (0%) | 11-19 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Exscientia plc is a pioneering pharmatech firm that leverages artificial intelligence (AI) to revolutionize drug discovery and development. The company provides a comprehensive, AI-driven platform that spans the entire drug development lifecycle. This integrated system supports crucial stages, including identifying disease targets, designing potential drug candidates, developing translational models, and optimizing patient selection for clinical trials. A key area of focus for Exscientia is the development of small molecule drug candidates. Through its advanced AI capabilities, the platform not only facilitates the efficient design of novel drug molecules but also employs AI-guided assessments to ensure patients receive the most suitable therapeutic interventions. Established in 2012, Exscientia plc is headquartered in Oxford, United Kingdom.
Thu, 24 Apr 2025
Exscientia Plc (EXAI) Stock Price, News & Analysis - Stock Titan
Fri, 11 Oct 2024
Recursion’s All-Stock Acquisition of Exscientia plc (EXAI): NVIDIA-Backed Merger to Revolutionize AI-Driven Drug Discovery - Yahoo Finance
Sat, 31 Aug 2024
Exscientia Plc (EXAI): A Penny Stock That Will Make You a Millionaire - Yahoo Finance
Thu, 08 Aug 2024
Recursion's Acquisition Of Exscientia Makes Sense On Some Levels, Not Others (NASDAQ:EXAI) - Seeking Alpha
Tue, 21 May 2024
Shareholders of Exscientia plc Should Contact The Gross Law Firm Before June 25, 2024 to Discuss Your Rights - EXAI - PR Newswire
Wed, 15 May 2024
Class Action Filed Against Exscientia plc (EXAI) Seeking Recovery for Investors - Contact Levi & Korsinsky - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|